LEGN (Legend Biotech) Inventories, Finished Goods : $0.4 Mil (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Legend Biotech Inventories, Finished Goods?

Legend Biotech's quarterly finished goods declined from Mar. 2024 ($1.7 Mil) to Jun. 2024 ($0.6 Mil) and declined from Jun. 2024 ($0.6 Mil) to Sep. 2024 ($0.4 Mil).

Legend Biotech's annual finished goods increased from Dec. 2021 ($0.0 Mil) to Dec. 2022 ($2.7 Mil) and increased from Dec. 2022 ($2.7 Mil) to Dec. 2023 ($3.3 Mil).

Legend Biotech Inventories, Finished Goods Historical Data

The historical data trend for Legend Biotech's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Legend Biotech Inventories, Finished Goods Chart

Legend Biotech Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventories, Finished Goods

Get a 7-Day Free Trial

2.68

3.29

Legend Biotech Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Inventories, Finished Goods	Get a 7-Day Free Trial															3.99	3.29	1.69	0.59	0.43

Legend Biotech Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

Legend Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Legend Biotech Corp (NAS:LEGN) » Definitions » Inventories, Finished Goods

Comparable Companies

Traded in Other Exchanges

9LB:Germany

Address

2101 Cottontail Lane, Somerset, NJ, USA, 08873

Website

https://www.legendbiotech.com

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.